The FDA and DEA Are At Odds Over CBD

The FDA thinks CBD should be rescheduled. On September 27, 2018, the DEA rescheduled Epidiolex, a cannabis-derived CBD tincture manufactured by GW Pharmaceuticals. But the FDA’s recommendation to reschedule CBD wasn’t supposed to apply only to Epidiolex.